Qiagen (QGEN) Stock
Established molecular diagnostics provider serving global research and testing. Here's the price, business snapshot, and what's worth knowing about Qiagen in October 2026.
Qiagen NV (QGEN) is an established provider of sample and assay technologies used in molecular diagnostics, life-science research and applied testing. The company's tools and kits help laboratories detect and analyse DNA, RNA and proteins — supporting areas such as infectious-disease testing, oncology, and personalised medicine. Revenue comes from recurring sales of consumables and instruments plus growing services tied to companion diagnostics and molecular tests. Geographic reach is global, exposing the business to developed and emerging market dynamics. Key catalysts include continued demand for molecular testing, expansion in oncology testing and the adoption of precision therapies. Investors should weigh these opportunities against risks: reimbursement pressure, regulatory scrutiny, competition from other diagnostics firms, foreign-exchange swings and possible volatility in instrument sales. With a market capitalisation near $10.5bn, Qiagen may suit investors seeking exposure to diagnostic technologies, but returns are not guaranteed. This is general information and not personal financial advice; consider your investment objectives and risk tolerance.
Qiagen (QGEN) Stock Forecast
Analyst price target, next 12 months
$50.66
+13.2% vs today's $44.75
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Qiagen have a consensus 12-month target of $50.66, above the current price of $44.75.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying QIAGEN's stock with a target price of $50.66, indicating potential growth.
Financial Health
QIAGEN is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
QIAGEN's projected dividend yield of 0.24% is low, indicating limited returns for dividend-focused investors. If you invested $1000, you would be paid $2.40 a year in dividends (based on the last 12 months).
Discover More Opportunities
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
Why You’ll Want to Watch This Stock
Recurring Consumables Revenue
Qiagen earns steady revenue from consumables and reagents that labs repurchase regularly, though sales can fluctuate with testing demand.
Global Diagnostics Reach
A broad international footprint gives exposure to varied markets and growth opportunities, but also brings foreign‑exchange and regional regulatory risks.
Oncology & Precision Medicine
Growth in companion diagnostics and personalised therapies could be a catalyst, while competition and reimbursement remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
